Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Vasc Health Risk Manag. 2011;7:391-7. doi: 10.2147/VHRM.S17168. Epub 2011 Jun 23.

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials.

Author information

  • 1Department of Cardiology, University Hospital of Saarland, Homburg Saar, Germany. magnus@baumhaekel.de


Activation of the renin-angiotensin system plays a major role in cardiovascular morbidity and mortality. Recently, angiotensin II receptor blockers (ARBs) have been the subject of a number of large clinical cardiovascular outcome trials, indicating beneficial effects of ARBs with more than 384,000 patient-years of data in different cardiovascular diseases along the cardiovascular continuum, from patients with risk factors, through high cardiovascular risk, to patients with heart failure. This article reviews the implications of these trials for the optimal management of cardiovascular risk.


angiotensin receptor blockers; cardiovascular outcome; clinical trials

[PubMed - indexed for MEDLINE]
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 1
Figure 2
Figure 3
Figure 4
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk